Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Up 16% This Year, How Long Can Procter & Gamble Continue Outperforming the S&P 500?

Procter & Gamble is topping the broader market this year, but it may be part of a cautionary tale.

Procter & Gamble (PG) has shown remarkable growth this year, up 15.6% year-to-date, outperforming the S&P 500 by 320 basis points. As one of the largest consumer staples companies by market capitalization, PG's stock performance is noteworthy, being one of just 13 Dow Jones Industrial Average components that have increased by at least 10% this year.

This impressive run has contributed to PG's status as a Dividend King, with a 50-year streak of dividend increases and a yield of 2.7%, more than double that of the S&P 500. Some investors are drawn to PG over higher-yielding Treasuries due to its potential for long-term upside. The current strength in consumer staples stocks can be attributed to the skittishness surrounding AI investments, which has led investors to seek refuge in defensive sectors like consumer staples.

However, the rich valuation of the sector, with the S&P 500 Consumer Staples Index having a higher price-to-earnings ratio compared to technology, may raise concerns. Some experts suggest that the shift from tech stocks to defensive stocks could signal a warning sign of potential market weakness. While it remains uncertain whether this prediction holds true, if it does, the outperformance of staple stocks, including PG, may simply be a case of "less bad."

As always, investors should carefully consider the valuation and potential risks before making investment decisions.

Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at fool.com →

More in Finance & Markets

Down 70% in 2026, Has Tilray's Stock Finally Bottomed Out?

The cannabis stock has generated nearly $1 billion in revenue over the past year, and its market cap is less than half of that.

  • Tilray stock down 70% in 2026, investors question bottom
  • Canadian cannabis firm seeks U.S. market growth
  • $963M revenue, $60.5M operating loss despite expansion

More from Tuesday 27 October →